Li Shuai – CEO, SIMR, China
Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the…
Address: Guilinyang Industrial Development Zone, Haikou, Hainan, China
Tel: 0898-65710069
Hainan Dongfang Dahui Starch Products Co., Ltd. is a national key leading enterprise in agricultural industry which owned the state’s financial investment, integrating cassava cultivation, production , deep-processing, etc, and owning 6 production lines to produce chemical modified starch, drying modified starch, pre-gelatinized modified starch, glutinous rice starch, etc, which supply series of high-quality cassava starch and modified starch products, widely used in the fields of food, paper, textile, feed, construction materials, petroleum, chemical industry, etc.. It has passed Certification of ISO9001-2008 Quality Management System, and HACCP-EC-01 Certification of Food Safety Management System. In 2006, it is honored as National Agricultural Products Processing Demonstration Enterprise by China Agricultural Department. Meanwhile, it is the only manufacture of organic cassava starch in China, which passed the organic certification of Canada, USDA, IFOAM and OFDC organization.
Food Series
Modified starch glue prime
Feed Series
Chemical Building Materials Series
Modified starch glue prime
Petroleum chemicals Series
Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the…
Zhenkun Ma, founder and CEO of TenNor Therapeutics, shares his cross-sectorial experiences in Big Pharma, biotech and non-profit organization that led to the establishment of TenNor Therapeutics; their mission to…
The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial…
Competition is heating up among Asian stock exchanges hoping to lure the hottest prospects in Chinese biotech to list there. The newest competitor, Shanghai’s STAR Board, has already attracted over…
Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking…
Dr Kai Lamottke, co-founder and MD of Bicoll GmbH, Munich, and since 2001, GM and board member of Bicoll Biotechnology (Shanghai) Co. Ltd discusses Bicoll’s presence in both the Chinese…
Jim Xu, GM of Medidata China, shares the importance of the China market to Medidata Solutions, the global leader in cloud services and solutions to the life sciences industry; his…
Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which…
Tony Acciarito, President of Thermo Fisher Scientific China, explains how he is delivering the company’s mission of ‘enabling our customers to make the world healthier, cleaner and safer’ in China,…
Zheru Zhang and Jielun Zhu of I-Mab Biopharma, shares their vision for the ambitious biotech company looking to develop their dual-pronged strategy of in-licensing ‘fast-to-market’ assets for their China portfolio…
Junshi Biosciences is an innovation-driven biopharmaceutical company with a focus on discovery and innovative drugs. Dr Li Ning, CEO, discusses being the first Chinese company to successfully launch a domestically-developed…
Kai Zhang, founder and chairman, and Sonia Wang, CEO, of Chinese respiratory technology specialist Omni Pharmaceuticals, discuss the respiratory market in China, how Omni plans to introduce four respiratory drugs…
See our Cookie Privacy Policy Here
